Purchase order for enriched Barium-137 at ASP Isotopes (ASPI)

Rhea-AI Filing Summary

ASP Isotopes Inc. reported that it has received a purchase order for enriched Barium-137 from a U.S.-based customer. This order relates to the company’s specialized isotope products and reflects commercial demand from a domestic buyer.

The company communicated this development through a press release dated September 30, 2025, which is included as an exhibit to this report for investors seeking additional operational detail.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

0001921865false00019218652025-09-302025-09-30iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2025

ASP Isotopes Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41555		87-2618235
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

601 Pennsylvania Avenue NW, South Building, Suite 900 Washington, DC		20004
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (202) 756-2245

 Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01		ASPI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐ 

Item 7.01. Regulation FD Disclosure.

On September 30, 2025, ASP Isotopes Inc. (the “Company”) issued a press release announcing a purchase order for enriched Barium-137 from a U.S.-based customer.  A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated September 30, 2025, of ASP Isotopes Inc. announcing a purchase order for enriched Barium-137 from a U.S.-based customer.
104		Cover Page Interactive Date File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASP ISOTOPES INC.
Date: September 30, 2025	By:	/s/ Donald G. Ainscow
	Name:	Donald G. Ainscow
	Title:	Executive Vice President, General Counsel and Secretary

3

FAQ

What did ASP Isotopes Inc. (ASPI) disclose in this 8-K?

ASP Isotopes Inc. disclosed that it received a purchase order for enriched Barium-137 from a U.S.-based customer, communicated via a press release dated September 30, 2025.

Which item of the 8-K does the ASP Isotopes (ASPI) disclosure relate to?

The disclosure is made under Item 7.01, Regulation FD Disclosure, indicating the company is providing broadly available information to the market.

What product is involved in the ASP Isotopes (ASPI) purchase order?

The purchase order involves enriched Barium-137, one of ASP Isotopes Inc.’s specialized isotope products.

Who is the customer in the ASP Isotopes (ASPI) purchase order?

The customer is described as a U.S.-based customer. No additional customer-identifying details are provided in this disclosure.

Where can investors find more detail about the ASP Isotopes (ASPI) announcement?

More detail is provided in Exhibit 99.1, a press release dated September 30, 2025, attached to the report and incorporated by reference for informational purposes.

Does the ASP Isotopes (ASPI) 8-K include financial statements?

Under Item 9.01, the company lists exhibits, including the press release and the cover page interactive data file; no separate financial statements are listed in this excerpt.